Morningstar’s recent analysis suggests a "Buy" on Intellia Therapeutics, assigning a fair value of $85 per share, while the current trading price is significantly lower at $15.85.
Morningstar has issued a BUY recommendation on Sanofi SA, with an upgraded fair value target of $63 from $61 due to consistent revenue growth and strong performance in immunology and vaccine divisi
H. Lundbeck A/S, a prominent Danish pharmaceutical company, has announced its largest-ever acquisition, agreeing to buy U.S.-based Longboard Pharmaceuticals for $2.6 billion.
Motilal Oswal's research report has upgraded IPCA Laboratories to a "BUY" recommendation with a target price of Rs 1,950, an upside of 18% from its current market price of Rs 1,659.
